Sort
21,281 grants matching “influenza”
Role of B Lymphocytes In HIV Infection And Pathogenesis
$716,681Anthony S. Fauci · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI
Pneumonia Biology
$716,519Joseph P Mizgerd · Boston University Medical Campus · R35 · FY2020 · HL
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
$716,192Harvinder Singh Gill · Texas Tech University · R01 · FY2019 · AI
Combination nanovaccine-based immunization against influenza virus in the aged: immunity and protection
$716,177Marian L Kohut · Iowa State University · R01 · FY2023 · AI
Impact of Early-life Exposure to Semi-Volatile Organic Compounds (SVOCs) on Neonatal and Early Childhood Immune Function
$716,067Jennifer K Hoffman · Duke University · R01 · FY2022 · AI
Adenovirus Protease Regulation and Antiviral Development
$715,982Walter F. Mangel · Brookhaven Science Assoc-Brookhaven Lab · R01 · FY2006 · AI
Tissue resident memory T cells and chronic lung allograft dysfunction
$715,793Mark Eugene Snyder · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · HL
Alterations In Pulmonary Immune Function And Host Resistance In COX Null Mice
$715,549Darryl C Zeldin · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES
The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infection
$715,493Hongpeng Jia · Johns Hopkins University · R01 · FY2020 · AI
Research Project 2 The pregnancy AdaptOME
$715,267Boris Dominik Juelg · Massachusetts Institute Of Technology · U19 · FY2024 · AI
Differentiation of Common Respiratory Viruses and SARS
$715,172Mark Aaron Poritz · Biofire Defense, Llc. · U01 · FY2008 · AI
Mucosal Protection Against HIV Generated by PIV5 Priming and VLP Boosting
$715,150Paul W. Spearman · Emory University · R01 · FY2016 · AI
Parents, Pediatricians and Telephone Coaches Partner to Improve Control (PARTNER)
$715,076Jane M Garbutt · Washington University · R01 · FY2009 · HL
Adjuvant Development
$715,000David Johnson · Corixa Corporation · N01 · FY2013 · AI
Natural Killer cells and the Immunogenetics of COVID-19
$714,785Paul John Norman · University Of Colorado Denver · R01 · FY2022 · AI
REDES: a peer network and mobile health (mHealth) enhanced CHW model to maximize COVID-19 vaccination among low income Latinos
$714,762Kathleen R Page · Johns Hopkins University · R01 · FY2024 · MD
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
$714,696Natalie Exner Dean · University Of Florida · R01 · FY2019 · AI
Fusion: Vaccine conjugate technology to advance vaccine safety and efficacy
$714,601David Jay Burkhart · University Of Montana · R01 · FY2019 · AI
Natural Killer cells and the Immunogenetics of COVID-19
$714,601Paul John Norman · University Of Colorado Denver · R01 · FY2023 · AI
Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2
$714,282Anne Moscona · Columbia University Health Sciences · R01 · FY2024 · AI
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
$714,193David Michael Markovitz · University Of Michigan At Ann Arbor · R01 · FY2024 · AI
Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
$714,193David Michael Markovitz · University Of Michigan At Ann Arbor · R01 · FY2025 · AI
Multiscale modeling of influenza vaccination strategies for optimal T cell immunity
$714,104Jacob E Kohlmeier · Emory University · U01 · FY2018 · HL
ETS-family Transcription Factor Mediated Control of Pulmonary Inflammation Induced by Influenza Viruses
$713,913Nicholas S Heaton · Duke University · R01 · FY2024 · AI
Multiscale Computational Microscopy of HIV-1
$713,887Rommie E Amaro · University Of California, San Diego · R01 · FY2023 · AI